Revealing Impact of Microcollapse, CIN, and Protein Concentration on Lyo Cake

Microstructure CQAs
Full field-of-view pharmaceutical tablet microstructure image showing internal phase distribution and pore network
Publication Title

Revealing the Pore Structure Variance of Lyophilized Cakes from Microcollapse, Controlled Ice Nucleation, and Protein Concentration Changes

This study investigates the application of X-ray microscopy (XRM) as an advanced characterization tool for optimizing lyophilization cycles in pharmaceutical formulations. Utilizing non-invasive, high-resolution imaging, XRM provided comprehensive insights into the macro- and microstructural features of lyophilized cakes, revealing distinct differences attributable to lyophilization processing. High primary drying temperatures and aggressive conditions led to microstructural alterations, including fractures and microcollapse, while conservative drying methods resulted in more uniform and homogeneous structure. The controlled ice nucleation (CIN) process notably enhanced sublimation rates by forming extensive macroporous zones.

Calibrated intensity analysis via XRM detected variations in solid content, and high-resolution imaging highlighted subtle microstructural differences among samples, contributing to a deeper understanding of cake properties. Surface area measurements obtained from XRM showed a strong correlation with conventional BET analysis, validating its quantitative accuracy. Additionally, simulated diffusivity derived from XRM data correlated well with dry layer resistance values from thermocouple measurements, underscoring its utility in evaluating mass transport behaviors. XRM's non-destructive nature and detailed imaging capabilities make it a valuable complementary tool to existing characterization techniques, enabling more efficient cycle development and optimization.

Publication cover: Revealing impact of microcollapse, CIN, and protein concentration on lyophilized microstructure

Lisa Ma, Lokesh Kumar, Fred Lim, Shawn Zhang, Jeffrey Wong, Phil Yawman, and Debby Chang

In collaboration with the Genentech Inc. Pharmaceutical Development Department

AbbVie logo
AbbVie logo
Bausch Health logo
Bausch Health logo
Bristol Myers Squibb logo
Bristol Myers Squibb logo
Merck logo
Merck logo
Moderna logo
Moderna logo
Novartis logo
Novartis logo
Pfizer logo
Pfizer logo
Johnson & Johnson Innovative Medicine logo
Johnson & Johnson Innovative Medicine logo
Roche logo
Roche logo
Mirati Therapeutics logo
Mirati Therapeutics logo
Genentech logo
Genentech logo
Lonza logo
Lonza logo
AbbVie logo
AbbVie logo
Bausch Health logo
Bausch Health logo
Bristol Myers Squibb logo
Bristol Myers Squibb logo
Merck logo
Merck logo
Moderna logo
Moderna logo
Novartis logo
Novartis logo
Pfizer logo
Pfizer logo
Johnson & Johnson Innovative Medicine logo
Johnson & Johnson Innovative Medicine logo
Roche logo
Roche logo
Mirati Therapeutics logo
Mirati Therapeutics logo
Genentech logo
Genentech logo
Lonza logo
Lonza logo

Transform Your Program with Microstructure Science

Get started with a drug product digital twin.

A purple tablet dissolving